March 20, 2018
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in… Read More
learn more
March 20, 2018
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Updated clinical practice guidelines indicate, based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to recommend Optune® in… Read More
learn more
March 15, 2018
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
The clinical and preclinical research to be presented includes the application of Tumor Treating Fields in seven cancer types ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14… Read More
learn more
March 15, 2018
Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
The clinical and preclinical research to be presented includes the application of Tumor Treating Fields in seven cancer types ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14… Read More
learn more
